TWA
LCTX icon

TCI Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

TCI Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$150 – 1302
2023
Q1 		$150 Hold
100
– – ﹤0.01% 2365
2022
Q4 		$117 Hold
100
– – ﹤0.01% 2393
2022
Q3 		$0 Sell
100
-100
-50% -$147 ﹤0.01% 2443
2022
Q2 		$0 Hold
200
– – ﹤0.01% 2411
2022
Q1 		$0 Sell
200
-1,937
-91% -$3K ﹤0.01% 2345
2021
Q4 		$5K Buy
+2,137
New +$5K ﹤0.01% 1676
2019
Q1 		– Sell
-1,300
Closed -$1K – 1479
2018
Q4 		$1K Sell
1,300
-186
-13% -$285 ﹤0.01% 1250
2018
Q3 		$3K Hold
1,486
– – ﹤0.01% 931
2018
Q2 		$3K Hold
1,486
– – ﹤0.01% 951
2018
Q1 		$3K Hold
1,486
– – ﹤0.01% 860
2017
Q4 		$3K Hold
1,486
– – ﹤0.01% 915
2017
Q3 		$4K Hold
1,486
– – ﹤0.01% 783
2017
Q2 		$4K Hold
1,486
– – ﹤0.01% 812
2017
Q1 		$4K Hold
1,486
– – ﹤0.01% 769
2016
Q4 		$5K Buy
+1,486
New +$4.56K ﹤0.01% 776

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TCI Wealth Advisors's LCTX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 100 shares — an estimated $150 sold.

TCI Wealth Advisors first reported a position in LCTX in Q4 2016 and held it in 15 quarters. The position peaked at $5K in Q4 2021. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 100 Lineage Cell Therapeutics shares in Q2 2023, an estimated $150.
  • TCI Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 15 quarters.
  • TCI Wealth Advisors's Lineage Cell Therapeutics position peaked at $5K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.